We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...

Now, it’s worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for ...

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising ...

What Happened? Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported in Q2 CY2025, with sales up 12.1% year on year to $2.96 billion ...

Even with the S&P 500 near an all-time high, there are plenty of compelling growth, dividend, and value stocks to buy now.

Vertex's late-stage pipeline also gives investors several lottery tickets with great odds. The drugmaker is evaluating ...

Throughout the last three months, 10 analysts have evaluated Vertex Pharmaceuticals (NASDAQ: VRTX), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 11 trades. If ...

In the following chart, we are able to follow the development of volume and open interest of call and put options for Vertex Pharmaceuticals's big money trades within a strike price range of $300. ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is the leading drugmaker in the treatment of cystic fibrosis, a life-threatening genetic disease that causes infections to several organs, including the lungs ...